Resmed Inc at JPMorgan Healthcare Conference Transcript
Okay, good morning and welcome again to the JP Morgan Healthcare Conference. My name's Chris Cooper, I cover the Australian healthcare stocks here at JP Morgan.
This man needs no introduction, but, I'd like to hand over here to Mick Farrell, the CEO of ResMed.
Great, well, thanks Chris and look forward to having about 20 minutes of presentation and then 20 minutes of Q&A, so get your questions ready. I know Chris has a whole bunch from sell side, corporate side, and now back to the sell side, so welcome back Chris to ResMed. This presentation is on investor. ResMed.com. You can read our full disclaimers there about the forward-looking statements. Some of you are new to the ResMed story. I see a lot of familiar faces, in the room and I see some folks who are new. ResMed is a 36. A year old startup, it's a spin out from Baxter. My father bought the technology for about $1.2 million Aussie dollars, so it's about $800,000 US dollars. I just checked the market cap on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
